• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Pharmacogenomics Applications in Psychiatric Disorders

        互联网

        294
        Serious mental illnesses, including schizophrenia and major depressive disorder, result in considerable chronicity, morbidity, and mortality, and are amongst the leading causes of disability in the developed world. Despite advances in development of pharmacologic agents over the last two decades, only about one-third of patients with psychotic or affective disorders experience rapid or robust treatment response, while as many as 40–50% can be labeled as partially or com pletely treatment refractory. Pharmacogenetic studies offer the potential to enhance clinical prognosis, and ultimately to tailor individualized therapies; however, the psychiatric pharmacogenetic literature to date may give the appearance of diverse, unreplicated results of uncertain clinical significance. To overcome this impression, we review findings demonstrating a replicable role in clinical prediction#x2014;for both symptom response and side effect burden—of several polymorphisms in genes in the serotonin and dopamine systems. We also highlight the limitations in current research, including the role of ethnic heterogeneity, the need to study treatment-na� patients, the lack of cost-benefit pharmacoeconomic studies, and the need for more comprehensive genotyping/haplotyping. We conclude by demonstrating the potential role of novel technologies, specifically whole genome association, in identifying robust, novel loci for pharmacogenomic prediction.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序